

### **Remarks**

By this amendment, the specification is amended to include sequence identifiers for the sequences listed in FIG. 12. Applicants note that the Office stated that five sequence identifiers were required. However, the p28ING5 amino acid sequence included within FIG. 12 is SEQ ID NO: 2, which was included in the original sequence listing. Therefore, only four new sequence identifiers (SEQ ID NOs: 3-6) have been added to the sequence listing in order to comply with 37 C.F.R. §§ 1.821-1.825. A replacement Sequence Listing (including SEQ ID NOs: 1-6) in both paper and electronic format is submitted herewith.

No new matter has been added by this filing.

### **Conclusion**

It is respectfully submitted that the sequence disclosures hereby comply with 37 C.F.R. §§ 1.821-1.825. If any issues remain, the Examiner is requested to contact the undersigned attorney.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Karri Kuenzli Bradley/  
Karri Kuenzli Bradley, Ph.D.  
Registration No. 56,300